1987 Ph.D. in Chemistry (Highest Honors), University of Gent, Belgium
1993 B.Sc. in Chemistry (Distinction), University of Gent, Belgium
1993-1994 Graduate Teaching Assistant (University of Gent, Belgium)
1996-1998 Maître d' Assistant (Instructor), Department of Organic Chemistry, University of Geneva, Switzerland
1998-2003 Assistant Professor,Department of Biochemistry, UT Southwestern Med Ctr.
2003-2007 Associate Professor, Department of Biochemistry, UT Southwestern Med Ctr.
Since 2005 Co-Director (with Steven L. McKnight), Chemistry and Cancer Scientific Program of the Simmons Comprehensive Cancer Center, UTSW
2006-2007 Associate Professor, Simmons Comprehensive Cancer Center, UTSW
Since 2007 Full Professor
Since 2011 Julie and Louis Beecherl Jr. Chair in Medical Science
Dr. De Brabander has documented his scientific contributions in over 90 peer-reviewed publications (h-index 37) and 15 patents, and at >60 major conferences and named lectureships. Awards
1994 Prix STAS par l'Académie Royale des Sciences, des Lettres et des Beaux-Arts de Belgique (STAS-award from the Royal Academy of Sciences, Letters and Beautiful Arts of Belgium), December 10, 1994
1989-1992 Scholarship from the Institute for Scientific Research in Agriculture and Industry (Belgium)
1994-1995 Fellowship from the Swiss National Science Foundation
1995-1996 Fulbright-Hays Award
2001-2003 Alfred P. Sloan Research fellowship 2001-2003
2006 "Journal Award" from the editorial boards of Synlettand Synthesis
2004-2008 Academic Development Program Award from the Chemistry Council of Merck Research Laboratories
2014 Elected Fellow of the American Association for the Advancement of Sciences Scientific interests
Synthesis of complex small molecules with interesting biological function, discovery of novel small-molecule activators of programmed cell death, orexin receptor agonists for the treatment of narcolepsy, antitumor agents that selectively target tumor-derived neuronal stem cells and colon cancers with APC mutations, and anti-trypanosomal agents for the treatment of African Sleeping Disease. Key publications
1. A Medicinal Chemistry-Driven Approach Identified the Sterol Isomerase EBP as the Molecular Target of TASIN Colorectal Cancer Toxins. P. C. Theodoropoulos, W. Wang, A. Budhipramono, B. M. Thompson, N. Madhusudhan, M. A. Mitsche, J. G. McDonald, J. K. De Brabander, D. Nijhawan, J. Am. Chem. Soc.
2020, 142, 13, 6128–6138.
2. A Multipronged Approach Establishes Covalent Modification of β-Tubulin as the Mode of Action of Benzamide Anti-cancer Toxins. J. M. Povedano, R. Rallabandi, X. Bai, X. Ye, J. Liou, H. Chen, J. Kim, Y. Xie, B. Posner, L. Rice, J. K. De Brabander, D. G. McFadden, J. Med. Chem.
2020, 63, 22, 14054–14066.
3. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma, Shi, Y., Lim, S.K., Liang, Q., Iyer, S.V., Wang, H.-Y., Wang, Z., Xie, X., Sun, D., Chen, Y.-J., Tsabar, V., Gutin, P., Williams, N., De Brabander, J.K., Parada, L.F., Nature
, 567, 7748, 2019, 341-346. Website https://www.utsouthwestern.edu/labs/de-brabander/research/